Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005628 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005628: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00005628 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005628, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent soft tissue sarcoma.
Interventions
- BIOLOGICAL vitespen
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2001-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005628
The ClinicalTrials.gov registry entry for NCT00005628 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vitespen is the first listed.
NCT00005628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005628 about?
NCT00005628 is a clinical study titled "Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent soft tissue sarcoma.
What is the current status of trial NCT00005628?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-11. Estimated completion is 2001-08.
What interventions are being tested in trial NCT00005628?
The interventions under investigation include: vitespen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005628?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.